Format

Send to

Choose Destination
Cell Cycle. 2013 Oct 1;12(19):3159-64. doi: 10.4161/cc.26062. Epub 2013 Aug 26.

Wee1 kinase as a target for cancer therapy.

Author information

1
Center for Cancer Research; National Cancer Institute; Bethesda, MD USA.

Abstract

Wee1, a protein kinase, regulates the G 2 checkpoint in response to DNA damage. Preclinical studies have elucidated the role of wee1 in DNA damage repair and the stabilization of replication forks, supporting the validity of wee1 inhibition as a viable therapeutic target in cancer. MK-1775, a selective and potent small-molecule inhibitor of wee1, is under clinical development as a potentiator of DNA damage caused by cytotoxic chemotherapies. We present a review of the role of wee1 in the cell cycle and DNA replication and summarize the clinical development to date of this novel class of anticancer agents.

KEYWORDS:

DNA damage; G2 checkpoint; MK 1775; cell cycle; cyclin-dependent kinase

PMID:
24013427
PMCID:
PMC3865011
DOI:
10.4161/cc.26062
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center